Sangamo Therapeutics, Inc (NASDAQ: SGMO)

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is a genomic medicine company that operates in the biotechnology industry, specifically focused on developing groundbreaking science into medicines that have the potential to transform the lives of patients and families afflicted with serious neurological diseases. The company's mission is to translate cutting-edge discoveries in genetics and epigenetics into effective therapies for patients with unmet medical needs.

Sangamo's main business activities are focused on developing epigenetic regulation therapies to treat serious neurological diseases. The company's core neurology programs are centered on the development of therapies to treat chronic neuropathic pain, tauopathies, neurodegenerative diseases such as prion disease and amyotrophic lateral sclerosis (ALS), and Huntington's disease. Sangamo is also developing novel engineered AAV capsids enhanced for delivery to neurological targets. These programs are based on the company's proprietary zinc finger epigenetic regulators, which have been shown to be effective in preclinical studies, and its capsid engineering platform, which has the potential to expand delivery beyond currently available intrathecal delivery capsids.

The company generates revenue primarily through its product candidates, including its wholly-owned gene therapy product candidate, isaralgagene civaparvovec (ST-920), which is being evaluated in a Phase 1/2 study for the treatment of Fabry disease, and its CAR-Treg cell therapy program, which is being evaluated in a Phase 1/2 study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation. Sangamo's customers include biopharmaceutical companies such as Pfizer, Takeda, and Biogen, with whom the company has collaborations to develop and commercialize its products. The company has received approximately $817 million in upfront licensing fees, milestone payments, and proceeds from the sale of its common stock to collaborators, and has the opportunity to earn up to $1.9 billion in potential future milestone payments.

Sangamo's competitive advantages include its proprietary zinc finger epigenetic regulators and its capsid engineering platform. These advantages position the company well in the gene therapy and gene editing space, where key competitors include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.

In terms of its financial position, Sangamo's cash, cash equivalents, and marketable securities as of December 31, 2023 are expected to allow the company to meet its liquidity requirements only into the third quarter of 2024. The company is actively seeking substantial additional capital to fund its operations and support its research and development endeavors, including to progress its preclinical and clinical programs. If the company is unable to secure additional funding, it may seek protection under the U.S. Bankruptcy Code.

Sangamo's product candidates include several programs focused on the treatment of serious neurological diseases, including chronic neuropathic pain, tauopathies, neurodegenerative diseases such as prion disease and amyotrophic lateral sclerosis (ALS), and Huntington's disease. The company's lead wholly-owned neurology programs are focused on the downregulation of the Nav1.7 sodium channels to treat chronic neuropathic pain, and the repression of prion gene expression to treat prion disease.

Sangamo's proprietary zinc finger DNA-binding domain (ZFP) technology platform is designed to generate highly specific ZFNs for genome editing and ZF-transcriptional regulators for epigenetic regulation using a range of proprietary methods. Sangamo's ZFPs are naturally occurring sequence-specific DNA-binding proteins in humans that recognize and bind to a specific DNA sequence within or near a particular gene and causes expression of that gene to be "turned on" (activated) or "turned off" (repressed). Sangamo's engineered DNA-binding zinc finger array is then linked to a functional domain, such as an activation or repression domain, to create a ZF-transcriptional regulator (ZFR). ZFRs have the potential to regulate the expression of a target gene, and can be used to repress several genes in a single cell. The company has several preclinical programs evaluating the potential of ZFRs that have been designed to down- or up-regulate the expression of genes as potential treatments for neurological diseases.

In addition to its ZFP technology platform, Sangamo is developing a proprietary AAV capsid engineering platform, SIFTER, with the aim of engineering capsids with improved CNS transduction. The company is applying SIFTER to screen tens of millions of unique capsids in order to identify certain capsids that mediate superior delivery to the CNS. Successive rounds of screening are conducted to find capsids that reproducibly demonstrate a desired therapeutic profile.